Communiqués Percheron Therapeutics Limited

Actions

PER

AU0000317281

Recherche biotechnologique et médicale

Cours en clôture Australian S.E. 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,004000 ^AUD	0,00%		0,00%	-55,56%

31/08	Percheron Therapeutics Limited annonce des changements au sein de son conseil d'administration	CI
19/08	Percheron Therapeutics Limited publie ses résultats annuels pour l'exercice clos le 30 juin 2026	CI

Communiqués

04/09	Edison Issues Report on Percheron Therapeutics (PER)	NE
27/11	Edison Issues Report on Percheron Therapeutics (PER)	NE
07/10/25	Edison Issues Report on Percheron Therapeutics (PER)	NE
19/09/25	Edison Issues Report on Percheron Therapeutics (PER)	NE
23/08/22	Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	GL
22/08/22	Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	GL
22/08/22	Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	AQ
22/06/22	New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2	AQ
22/06/22	New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2	GL
12/04/22	Antisense Therapeutics : Prospectus	PU
09/03/22	Antisense Therapeutics to present poster at world’s largest NMD conference	GL
09/03/22	Antisense Therapeutics to present poster at world’s largest NMD conference	GL
27/01/22	Antisense Therapeutics : Application for quotation of securities - ANP	PU
26/01/22	Antisense Therapeutics : Quarterly Report and Appendix 4C	PU
24/12/21	Antisense Therapeutics : Application for quotation of securities - ANP	PU
22/12/21	Antisense Therapeutics : Application for quotation of securities - ANP	PU
15/12/21	Antisense Therapeutics : Annual General Meeting Presentation	PU
23/11/21	Antisense Therapeutics : Update - Proposed issue of securities - ANP	PU
02/07/21	Antisense Therapeutics : Morgans rates ANP as Add	AQ
11/06/20	Antisense Therapeutics : Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website	BU
21/05/20	Antisense Therapeutics : ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints	BU
27/02/20	Antisense Therapeutics : Announces Appointment of US-based Consultant Medical Director	BU
09/11/15	Antisense Therapeutics : Appointment of Non-Executive Director (G Pace)	PU
04/11/15	Antisense Therapeutics : ATL1103: Data Presentation at the Society for Endocrinology BES 2015 Conference	PU
04/11/15	Antisense Therapeutics : Change of Directors Interest Notice (RM)	PU